Chemotherapy-induced peripheral neuropathy common after taxane therapy for breast cancer
Click Here to Manage Email Alerts
Two-thirds of patients with breast cancer treated with taxane-based therapy experienced clinically meaningful chemotherapy-induced peripheral neuropathy symptoms during the first year of treatment, according to prospective study results.
Nearly half continued to experience these symptoms at the end of the first year of treatment, findings of the SWOG S1714 study presented at San Antonio Breast Cancer Symposium showed.
The results support the need to develop more effective strategies to prevent and treat this adverse effect, as well as predict those who are at greatest risk, investigators concluded.
Healio spoke with Meghna S. Trivedi, MD, MS, medical oncologist and co-leader of the hereditary breast and ovarian cancer program at Columbia University Herbert Irving Comprehensive Cancer Center, about the findings and their potential implications.
Collapse
Trivedi MS, et al. Abstract PD8-06. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2023; San Antonio.
Click Here to Manage Email Alerts